Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Clinical trial NCT05392946 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05392946
- Sponsor
- Mayo Clinic
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-11
- Primary completion
- 2026-09-29
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.